Search Results
Dr. Srdan Verstovsek on JAK2 Inhibitors as a Treatment for Myelofibrosis
Update on JAK2 Inhibitors by Srdan Verstovsek, MD
Update on JAK2 Inhibitors by Srdan Verstovsek, MD
Dr. Verstovsek Discusses Immunotherapy in Myelofibrosis
Srdan Verstovsek, MD, on the Phase III VERIFY Trial
Second-line myelofibrosis treatment – the potential of JAK2 inhibitor NS-018
Beyond JAK2 Inhibitors: New targets and new agents
Update on JAK Inhibitors for Myelofibrosis: There is more than one
Management of Myelofibrosis: JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting
Dr. Verstovsek, MD, PhD-New Approaches for MF
New MPN Treatments and Drugs - Srdan Verstovsek, MD, PhD
If a patient's PMF is wild-type JAK, what is your recommendation for treatment?
